» Articles » PMID: 23896435

CAG Size-specific Risk Estimates for Intermediate Allele Repeat Instability in Huntington Disease

Overview
Journal J Med Genet
Specialty Genetics
Date 2013 Jul 31
PMID 23896435
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: New mutations for Huntington disease (HD) occur due to CAG repeat instability of intermediate alleles (IA). IAs have between 27 and 35 CAG repeats, a range just below the disease threshold of 36 repeats. While they usually do not confer the HD phenotype, IAs are prone to paternal germline CAG repeat instability. Consequently, they may expand into the HD range upon transmission to the next generation, producing a new mutation. Quantified risk estimates for IA repeat instability are extremely limited but needed to inform clinical practice.

Methods: Using small-pool PCR of sperm DNA from Caucasian men, we examined the frequency and magnitude of CAG repeat instability across the entire range of intermediate CAG sizes. The CAG size-specific risk estimates generated are based on the largest sample size ever examined, including 30 IAs and 18 198 sperm.

Results: Our findings demonstrate a significant risk of new mutations. While all intermediate CAG sizes demonstrated repeat expansion into the HD range, alleles with 34 and 35 CAG repeats were associated with the highest risk of a new mutation (2.4% and 21.0%, respectively). IAs with ≥33 CAG repeats showed a dramatic increase in the frequency of instability and a switch towards a preponderance of repeat expansions over contractions.

Conclusions: These data provide novel insights into the origins of new mutations for HD. The CAG size-specific risk estimates inform clinical practice and provide accurate risk information for persons who receive an IA predictive test result.

Citing Articles

Ubiquitin specific peptidase 11 knockdown slows Huntington's disease progression via regulating mitochondrial dysfunction and neuronal damage depending on PTEN-mediated AKT pathway.

Gao B, Jing Y, Li X, Cong S Mol Med. 2025; 31(1):7.

PMID: 39780069 PMC: 11715466. DOI: 10.1186/s10020-024-01061-w.


Regulation of mRNA Biogenesis: The Norm and Pathology.

Zubkova A, Yudkin D Int J Mol Sci. 2024; 25(21).

PMID: 39519046 PMC: 11546943. DOI: 10.3390/ijms252111493.


Exploring the therapeutic potential: Apelin-13's neuroprotective effects foster sustained functional motor recovery in a rat model of Huntington's disease.

Torkamani-Dordshaikh S, Darabi S, Norouzian M, Bahar R, Beirami A, Moghaddam M Anat Cell Biol. 2024; 57(3):419-430.

PMID: 39079710 PMC: 11424562. DOI: 10.5115/acb.23.284.


Somatic CAG repeat instability in intermediate alleles of the HTT gene and its potential association with a clinical phenotype.

Ruiz de Sabando A, Ciosi M, Galbete A, Cumming S, Monckton D, Ramos-Arroyo M Eur J Hum Genet. 2024; 32(7):770-778.

PMID: 38433266 PMC: 11220145. DOI: 10.1038/s41431-024-01546-6.


Highly Potent Peptide Therapeutics To Prevent Protein Aggregation in Huntington's Disease.

Khan A, Ozcelik C, Begli O, Oguz O, Kesici M, Kasirga T ACS Med Chem Lett. 2023; 14(12):1821-1826.

PMID: 38116434 PMC: 10726468. DOI: 10.1021/acsmedchemlett.3c00415.